Christopher W. Murray

Papers

Total Citations

340

H-Index

About

Christopher W. Murray is a leading figure in computational chemistry and drug discovery, with a career defined by bridging the gap between structural biology and small-molecule design. His seminal 2005 review, "Structural biology and drug discovery," which has garnered over 340 citations, remains a cornerstone reference for researchers seeking to integrate protein structures into the drug development pipeline. Murray's major contributions lie in the development and application of fragment-based drug discovery (FBDD) and structure-based design, where he has pioneered methods for identifying and optimizing weak-binding fragments into potent clinical candidates. His work has directly influenced the discovery of multiple drug leads, particularly in oncology and infectious diseases, demonstrating the power of combining X-ray crystallography with computational modeling. Beyond his high-impact publications, Murray is recognized for his leadership at Astex Pharmaceuticals, where he drove the company's fragment-based platform to success, and for mentoring a generation of scientists in the practical application of biophysics to drug design. His research continues to shape how the pharmaceutical industry approaches challenging targets, making him an essential figure for students and researchers interested in the molecular foundations of therapeutics.